Author

S. Iwanami

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 6 Evolutionary Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 4 Approach:statistical model· 4 Assay:bulk RNA-seq· 2 Research Focus:host-pathogen & immune response· 2 Organism:human· 2 Organism:virus· 2 Research Focus:cell type annotation· 1

Frequent Co-Authors

S. Iwami· 7 shared K. Watashi· 6 shared H. Ohashi· 5 shared K. S. Kim· 4 shared K. Shionoya· 4 shared T. Suzuki· 4 shared T. Wakita· 3 shared Y. Takahashi· 3 shared

Activity by Year

2019-2024 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

7 shared papersMicrobiology

S. Iwami

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Stratification of viral shedding patterns in saliva of COVID-19 patients

H. Park, Y. Raiki, S. Iwanami, K. Kim, K. Ejima, N. Nakamura, K. Aihara, Y. Miyazaki, T. Umeyama, K. Miyazawa, T. Morita, K. Watashi, C. B. Brooke, R. Ke, S. Iwami, T. Miyazaki

This study stratifies SARS-CoV-2 viral shedding patterns in saliva into three groups with distinct durations using a mathematical model and clustering, but finds no clear clinical or miRNA biomarkers explaining the differences.

bioRxiv · Jan 30, 2024Microbiology

Potential anti-monkeypox virus activity of atovaquone, mefloquine, and molnupiravir, and their potential use as treatments

D. Akazawa, H. Ohashi, T. Hishiki, T. Morita, S. Iwanami, K. S. Kim, Y. D. Jeong, E.-S. Park, M. Kataoka, K. Shionoya, J. Mifune, K. Tsuchimoto, S. Ojima, A. H. Azam, S. Nakajima, , K. Watashi

This study identifies atovaquone, mefloquine, and molnupiravir as potential anti-monkeypox virus drugs, with atovaquone showing enhanced efficacy when combined with tecovirimat.

bioRxiv · Aug 2, 2022 · PreprintMicrobiology

Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2

H. Ohashi, T. Hishiki, D. Akazawa, K. S. Kim, J. Woo, K. Shionoya, K. Tsuchimoto, S. Iwanami, S. Moriyama, H. Kinoshita, S. Yamada, Y. Kuroda, T. Yamamoto, N. Kishida, S. Watanabe, , K. Watashi

The paper compares the efficacy of neutralizing antibodies and antiviral drugs against SARS-CoV-2 Omicron subvariants BA.1 and BA.2, finding differential responses to specific treatments.

bioRxiv · Feb 27, 2022Microbiology

Characterization of various remdesivir-resistant mutations of SARS-CoV-2 by mathematical modeling and molecular dynamics simulation.

S. Torii, K. S. Kim, J. Koseki, R. Suzuki, S. Iwanami, Y. Fujita, Y. D. Jeong, Y. Matsuura, T. Shimamura, S. Iwami, T. Fukuhara

This study identifies remdesivir-resistant SARS-CoV-2 mutations using viral reconstruction, mathematical modeling, and molecular dynamics simulations, showing mutations reduce antiviral activity without increasing viral production.

bioRxiv · Feb 22, 2022 · PreprintMicrobiology

Anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) potency of Mefloquine as an entry inhibitor in vitro

K. Shionoya, M. Yamasaki, S. Iwanami, Y. Ito, S. Fukushi, H. Ohashi, W. Saso, T. Tanaka, S. Aoki, K. Kuramochi, S. Iwami, Y. Takahashi, T. Suzuki, M. Muramatsu, M. Takeda, , K. Watashi

This study identifies Mefloquine as a potent in vitro entry inhibitor of SARS-CoV-2 with higher antiviral activity than Hydroxychloroquine.

bioRxiv · Nov 19, 2020Microbiology

Multidrug treatment with nelfinavir and cepharanthine against COVID-19

H. Ohashi, K. Watashi, W. Saso, K. Shionoya, S. Iwanami, T. Hirokawa, T. Shirai, S. Kanaya, Y. Ito, K. S. Kim, K. Nishioka, S. Ando, K. Ejima, Y. Koizumi, T. Tanaka, , T. Wakita

This study identifies a new multidrug combination treatment for COVID-19 using nelfinavir and cepharanthine, showing synergistic antiviral effects and improved disease control.

bioRxiv · Apr 14, 2020 · PreprintMicrobiology

Two strategies underlying the trade-off of hepatitis C virus proliferation: stay-at-home or leaving-home?

S. Iwanami, K. Kitagawa, Y. Asai, H. Ohashi, K. Nishioka, H. Inaba, S. Nakaoka, T. Wakita, O. Diekmann, S. Iwami, K. Watashi

This study analyzes the trade-off between two HCV proliferation strategies, finding that Jc1-n favors transmission while JFH-1 favors intracellular replication.

bioRxiv · Oct 28, 2019Evolutionary Biology